Companies Who Were in the Room:
Harness the Expanding Analytical Toolbox & Ensure Process Quality at Every Phase to Demonstrate Safety, Efficacy & Consistency of Gene Therapies to Regulators
Thank you to our speakers, sponsors, and delegates who joined us in Boston for the summit! If you are interested in other upcoming events, please get in touch at info@hansonwade.com
What You Missed at the 6th Gene Therapy Analytical Development & CMC Summit
Execute Robust Analytical & Process Development Strategies for Complex Gene Therapies
Twelve gene therapies have been approved by the FDA to date to treat a variety of diseases, including the first ever gene edited therapeutic. The CMC package required to effectively demonstrate safety and efficacy of increasingly complex gene therapy products to regulators needs to keep pace.
The 6th Gene Therapy Analytical Development & CMC Summit unites 250+ analytical development, CMC, QC, and process development experts to showcase innovative analytical and process development methods, assess their readiness, and ultimately guarantee the safety, quality, efficacy, and consistency of gene therapies to regulators.
Your Complete Guide to the 2024 Meeting is Here:
Previously Attending Companies Include:
"Gene Therapy Analytical Summit is a one-of-a-kind conference where focus is on analytical methods for gene therapy. This focused conference brings together expertise, findings and conversation around current challenges. It is a very relevant and meaningful conferences the best conference in the field"
Binod Pandey, Senior Scientist, Novartis
Our Senior 2024 Partners:
Other Events In The Gene Therapy Series:
